AUSTIN, Texas, Feb. 14, 2011 /PRNewswire/ -- SpineSmith, a Texas-based medical device company, today announces the company will begin the national rollout in March of the VisuALIF, following a successful Alpha launch.
The VisuALIF is a two-piece, stand alone device indicated for intervertebral body fusion of the lumbar spine that received FDA clearance for commercial sale in the United States in October 2010. VisuALIF is the first modular lumbar interbody device with an open-face allowing in situ graft placement, tactile feedback with face plate attachment and device placement flush with the anterior aspect of the vertebrae. The device is available in a range of product sizes and configurations designed to meet surgeon requirements across a wide spectrum of patient anatomy.
Brian Burkinshaw, SpineSmith’s Vice President of Engineering, believes the VisuALIF offers a unique solution for surgeons. “The VisuALIF incorporates an anterior open-face, allowing surgeons to visualize end plate preparation post-placement, leading to optimum graft placement with respect to larger available volumes. During our alpha launch we received positive feedback regarding the implant and have fine-tuned our instrumentation to create a best in class system relative to surgeon ease of use.”
Chuck Reynolds, Vice President of Sales, and his team are currently expanding the company’s sales distribution network, while enhancing the new product training program on the strength of the alpha launch feedback. Mr. Reynolds states; “We are continuing to build momentum for the VisuALIF by enlarging the national sales distribution network while working with premier spine surgeons and institutions during the national roll out.”
About SpineSmith Partners LP
SpineSmith Partners LP designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. We take a different approach from other companies, utilizing a collaborative approach between scientists, engineers and spine surgeons. Our unique approach gives spine surgeons the ability to directly impact the direction of our product portfolio, ensuring applicability and achieving the highest standards of patient care. For more information please visit: www.spinesmithusa.com.
About Celling Technologies
Celling Technologies, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine. Celling’s product offering focuses on autologous adult stem cell therapy and the devices and services that compliment these procedures. For more information please visit: www.cellingtechnologies.com.
CONTACT: Ashlynn Russey, arussey@spinesmithusa.com
SOURCE SpineSmith Partners LP
